Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Equity Ratio (2020 - 2022)

Historic Equity Ratio for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q3 2022 value amounting to 0.97.

  • Atea Pharmaceuticals' Equity Ratio rose 4012.66% to 0.97 in Q3 2022 from the same period last year, while for Sep 2022 it was 0.97, marking a year-over-year increase of 4012.66%. This contributed to the annual value of 0.92 for FY2021, which is 4484.13% up from last year.
  • Atea Pharmaceuticals' Equity Ratio amounted to 0.97 in Q3 2022, which was up 4012.66% from 0.95 recorded in Q2 2022.
  • Atea Pharmaceuticals' 5-year Equity Ratio high stood at 0.97 for Q3 2022, and its period low was 0.69 during Q3 2020.
  • Over the past 3 years, Atea Pharmaceuticals' median Equity Ratio value was 0.7 (recorded in 2021), while the average stood at 0.64.
  • In the last 5 years, Atea Pharmaceuticals' Equity Ratio soared by 19920.05% in 2021 and then surged by 3593.37% in 2022.
  • Atea Pharmaceuticals' Equity Ratio (Quarter) stood at 0.63 in 2020, then surged by 44.84% to 0.92 in 2021, then rose by 5.14% to 0.97 in 2022.
  • Its last three reported values are 0.97 in Q3 2022, 0.95 for Q2 2022, and 0.95 during Q1 2022.